ShangHai JinFeng Wine (600616.SH): Chairman and General Manager Tang Wenjie resigns
Jinfeng Liquor (600616.SH) announced that the Board of Directors recently received the resignation application of Chairman and General Manager Tang Wenjie...
Announcement of Resignation from Shanghai JinFeng Wine (600616.SH): The Board of Directors of the company recently received the resignation application from the Chairman and General Manager Tang Wenjie. Due to work transfer, Tang Wenjie applied to resign from the positions of Director, Chairman, General Manager of the 11th Board of Directors, Director of the Board's Strategic Committee, and member of the Board's Compensation and Assessment Committee. After resigning from the above positions, Tang Wenjie will no longer hold any position in the company. The resignation report of Tang Wenjie will take effect from the date of delivery to the company's Board of Directors.
In view of Tang Wenjie's resignation, it is proposed to appoint Zhu Yong as a director of the company; it is decided to appoint Xu Lili as the Deputy General Manager of the company, and to act as the General Manager. The terms of office for the two aforementioned individuals will expire at the end of this term of the Board of Directors. The appointment of director will need to be submitted for approval at the shareholders' meeting.
Related Articles

Geely Auto (00175) and Volvo Car have signed a non-binding memorandum of understanding regarding the Lynk & Co European business.

GHW INTL (09933) announces annual performance net profit of 13.4 million yuan, a year-on-year increase of 3.9%.
Shenzhen Hepalink Pharmaceutical Group (09989) announced its annual performance with a net profit attributable to shareholders of 349 million yuan, a decrease of 45.96% year-on-year.
Geely Auto (00175) and Volvo Car have signed a non-binding memorandum of understanding regarding the Lynk & Co European business.

GHW INTL (09933) announces annual performance net profit of 13.4 million yuan, a year-on-year increase of 3.9%.

Shenzhen Hepalink Pharmaceutical Group (09989) announced its annual performance with a net profit attributable to shareholders of 349 million yuan, a decrease of 45.96% year-on-year.
RECOMMEND

Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026

Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026

Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026


